Trials / Completed
CompletedNCT05139680
A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis
Real-World Effectiveness of Tafamidis 80 mg or 61 mg on Neurologic Disease Progression in Patients With Mixed-Phenotype Hereditary Transthyretin Amyloid Cardiomyopathy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Hereditary Transthyretin Amyloidosis using data that already exist in patients' medical records.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tafamidis | 80 or 61 milligrams (mg) |
Timeline
- Start date
- 2023-03-08
- Primary completion
- 2023-05-19
- Completion
- 2023-05-19
- First posted
- 2021-12-01
- Last updated
- 2024-09-19
- Results posted
- 2024-09-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05139680. Inclusion in this directory is not an endorsement.